Background
The non-steroidal anti-inflammatory drug diflunisal has been shown to stabilize transthyretin (TTR) and thereby prevent amyloid fibril formation. After the international randomized, double blind, placebo-controlled diflunisal trial [1] was closed for enrolment in 2011, the Swedish DFNS01 study was started to continue monitoring the effect of diflunisal in patients with hereditary transthyretin (ATTRm) amyloidosis. Since TTR amyloid fibril composition has been shown to be important for disease outcome [2] , amyloid fibril type was taken into account when analysing the study results.
Material and methods
DFNS01 was a 24-month open-label observational study designed to monitor the effect of diflunisal 500 mg daily in ATTRm amyloidosis. It was open for enrolment from July 2011 to the publication of the controlled diflunisal trial. Primary outcome measure was changes in the Kumamoto scale [3] , and secondary outcome measures were changes in nutritional status (modified body mass index (mBMI), palbumin Â BMI) [4] , cardiac function (septal thickness, p-proBNP) and safety follow-up blood tests (b-haemoglobin, b-platelets, p-creatinine, p-liver enzymes). Evaluations were performed yearly. Amyloid fibril type was established from abdominal fat pad biopsies with Western blot analyses [2] . Late disease onset was defined as onset !50 years of age.
Results
Fifty-four patients were included and their baseline characteristics are shown in Table 1 . Of those included, 14 (26%) had received diflunisal prior to inclusion in DFNS01 with a median pre-study treatment of 2 (full range 0.1-4) years. Seventeen (31%) of the patients had completed the 24month study follow-up, whereas 37 (69%) had dropped out after a median duration of 10.8 (0.4-21.8) months. Thirtyfour patients had completed 12 months. The main reasons for early termination were study closure (40%), liver transplantation (24%), and side effects (19%). Of the nine 
Discussion and conclusions
Although limited by high dropout rates, mainly due to liver transplantation and study closure, the DFNS01 trial supports the safety and efficacy of diflunisal for ATTRm amyloidosis, and the results are in line with the previous placebo-controlled trial. Total Kumamoto scores and nutritional status remained stable, however, motor neuropathy scores and cardiac septum thickness increased significantly during the study, which suggests that complete disease stabilization is not achieved on group level. No obvious difference in outcome was noted with regard to amyloid fibril type, but the number of patients was low. Further studies are needed to evaluate the long-term effect of diflunisal and whether all sub-groups of patients have the same beneficial treatment effect.
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